The financing round comes as Color expands its partnerships with healthcare systems and builds out a national genetic counseling resource for NIH's All of Us program.
Framingham, Massachusetts-based Kephera's tests is intended to be used to differentiate neurocysticercosis from other causes of seizures in patients.
In seven years, the public variant classification database has steadily become a resource that labs are submitting to and that genetics experts are consulting.
The funding supports development of a low-cost platform for detection of antimicrobial resistance elements in complex microbial communities.
The seven-year grant renews funding for the Antibacterial Resistance Leadership Group, led by Duke University and UCSF, with $15 million in 2020.
Called Ion, the system combines low magnification, high-resolution imaging with a proprietary image analysis algorithm for rapid pathogen detection.
The company's Nanotrap technology uses hydrogel nanoparticles functionalized with internal affinity baits to enrich target analytes for downstream analysis.
The plan focuses on five scientific priorities to advance research and development over the next five years, including developing diagnostic tests for the diseases.
Acquired epilepsy is a form of the neurological disorder that results from other conditions such as stroke, infections, and traumatic brain injury.
Specific Diagnostics said it plans to apply CE marking to the Reveal system next year, followed by submission to the FDA for 510(k) clearance.